Drug Name: CNS10-NPC-GDNF
Company: Svendsen Lab
Location: Cedar-Sinai Medical Center Los Angeles, CA
Drug Type: Stem Cell Therapy
Conditions: ALS
Mechanism Type: Neuroprotection
Mechanism: CNS10-NPC-GDNF are genetically engineered human neural progenitor cells that secrete GDNF. The approach aims to use stem cells to deliver GDNF into the CNS in hopes to promote motor neuron survival.
U.S. Status for ALS: Phase I

[1] CNS10-NPC-GDNF for the Treatment of ALS., May 25, 2017.
[2] Glial cell line-derived neurotrophic factor-secreting human neural progenitors show long-term survival, maturation into astrocytes, and no tumor formation following transplantation into the spinal cord of immunocompromised rats. Neuroreport. 2014 Apr 16;25(6):367-72.

Last updated June 21st, 2017

Share this: